Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Study finds few new antibiotics are in the pipeline

20.04.2004


Trend comes despite critical public health need



Despite a critical need for new antibiotics to treat drug-resistant infections and other infectious diseases, very few new antibiotics are being developed, according to a study in the May 1 issue of Clinical Infectious Diseases, now available online.

To document trends, researchers evaluated Food and Drug Administration (FDA) databases of approved drugs and the research and development (R&D) programs of the world’s largest pharmaceutical and biotechnology companies, by looking at the companies’ websites and 2002 annual reports. They found that FDA approvals of new antibiotics declined 56 percent during the past 20 years (1998-2002 versus 1983-1987). Looking to the future, the researchers found only six new antibiotics in the R&D pipeline out of 506 drugs being developed. One of those drugs, telithromycin, was approved by FDA this month.


Bacteria, which are treated with antibiotics, are by far the most common cause of infectious-related deaths in the United States. Because of the emergence of drug-resistant bacteria, the researchers note that there are few or no treatment options for many infections.

Although the need for new antibiotics is increasing, a number of factors make these drugs less economically attractive than drugs that treat chronic diseases. "Pharmaceutical companies appear to be more interested in developing drugs that patients take for life, such as those used to treat hypertension or arthritis," said lead author Brad Spellberg, MD, of the Research and Education Institute and Department of Medicine at Harbor-UCLA Medical Center. "By comparison, antibiotics are usually prescribed for one or two weeks at most."

In addition, the researchers note that in order to prevent the evolution of resistant strains of bacteria, infectious disease physicians try very hard to limit the overuse of newer antibiotics. "This is absolutely required from a public health perspective," Dr. Spellberg said. "From the pharmaceutical companies’ perspective, it probably decreases sales for new antibiotics, making their development less attractive."

Dr. Spellberg said he believes that the lack of new antibiotics in development is caused by a complicated "systems problem," and not by irresponsibility on the part of the pharmaceutical companies, the FDA, or physicians. "Patients are in the middle of this issue, because they need new antibiotics, and it is our job to make sure that new ones come along despite the ’systems problem,’" he said.

Based on their review of the pipeline, the researchers conclude that the problem will worsen in the future, unless new incentives are developed to spur antibiotic R&D. "This may require remedies similar to approaches that have been taken in the arena of anti-cancer drugs and bioterrorism," said John E. Edwards, Jr., MD, also of Harbor-UCLA. Dr. Edwards serves on a task force of the Infectious Diseases Society of America (IDSA), which has made the development of new antibiotics a top policy priority, and he has testified on the issue before Congress. IDSA is developing proposals that will be presented to Congress and the Bush administration this spring.


Founded in 1979, Clinical Infectious Diseases publishes clinical articles twice monthly in a variety of areas of infectious disease, and is one of the most highly regarded journals in this specialty. It is published under the auspices of the Infectious Diseases Society of America (IDSA), a professional society representing more than 7,500 physicians and scientists who specialize in infectious diseases. For more information, visit www.idsociety.org.

Diana Olson | EurekAlert!
Further information:
http://www.idsociety.org

More articles from Studies and Analyses:

nachricht Self-organising system enables motile cells to form complex search pattern
07.05.2019 | Westfälische Wilhelms-Universität Münster

nachricht Mouse studies show minimally invasive route can accurately administer drugs to brain
02.05.2019 | Johns Hopkins Medicine

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: The hidden structure of the periodic system

The well-known representation of chemical elements is just one example of how objects can be arranged and classified

The periodic table of elements that most chemistry books depict is only one special case. This tabular overview of the chemical elements, which goes back to...

Im Focus: MPSD team discovers light-induced ferroelectricity in strontium titanate

Light can be used not only to measure materials’ properties, but also to change them. Especially interesting are those cases in which the function of a material can be modified, such as its ability to conduct electricity or to store information in its magnetic state. A team led by Andrea Cavalleri from the Max Planck Institute for the Structure and Dynamics of Matter in Hamburg used terahertz frequency light pulses to transform a non-ferroelectric material into a ferroelectric one.

Ferroelectricity is a state in which the constituent lattice “looks” in one specific direction, forming a macroscopic electrical polarisation. The ability to...

Im Focus: Determining the Earth’s gravity field more accurately than ever before

Researchers at TU Graz calculate the most accurate gravity field determination of the Earth using 1.16 billion satellite measurements. This yields valuable knowledge for climate research.

The Earth’s gravity fluctuates from place to place. Geodesists use this phenomenon to observe geodynamic and climatological processes. Using...

Im Focus: Tube anemone has the largest animal mitochondrial genome ever sequenced

Discovery by Brazilian and US researchers could change the classification of two species, which appear more akin to jellyfish than was thought.

The tube anemone Isarachnanthus nocturnus is only 15 cm long but has the largest mitochondrial genome of any animal sequenced to date, with 80,923 base pairs....

Im Focus: Tiny light box opens new doors into the nanoworld

Researchers at Chalmers University of Technology, Sweden, have discovered a completely new way of capturing, amplifying and linking light to matter at the nanolevel. Using a tiny box, built from stacked atomically thin material, they have succeeded in creating a type of feedback loop in which light and matter become one. The discovery, which was recently published in Nature Nanotechnology, opens up new possibilities in the world of nanophotonics.

Photonics is concerned with various means of using light. Fibre-optic communication is an example of photonics, as is the technology behind photodetectors and...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

SEMANTiCS 2019 brings together industry leaders and data scientists in Karlsruhe

29.04.2019 | Event News

Revered mathematicians and computer scientists converge with 200 young researchers in Heidelberg!

17.04.2019 | Event News

First dust conference in the Central Asian part of the earth’s dust belt

15.04.2019 | Event News

 
Latest News

Uncovering hidden protein structures

18.06.2019 | Life Sciences

Monitoring biodiversity with sound: how machines can enrich our knowledge

18.06.2019 | Life Sciences

Schizophrenia: Adolescence is the game-changer

18.06.2019 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>